Advances in the application of PD-1/PD-L1 immunotherapy for prostate cancer: a review
Frontiers in Immunology · 2025
DOI: 10.3389/fimmu.2025.1664587 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, 2025. Verfasst von Guangqiang Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine,…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Programmed Cell Death 1 Receptor, B7-H1 Antigen, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 232 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Prostate cancer (PCa), the most prevalent malignancy among male genitourinary cancers, is distinguished by its immunologically ”cold” phenotype with persistently high incidence and mortality. Radical prostatectomy and radiotherapy represent the current standard of care for localized prostate cancer. However, recurrence or progression occurs frequently, and advanced or metastatic disease is common at initial presentation. Recent progress in cancer immunotherapy reveals that modulation of immune responses represents an effective strategy for enhancing antitumor activity. Programmed Cell Death Protein 1 and Programmed Cell Death Ligand 1 (PD-1/PD-L1) inhibitors, which restore T-cell function and remodel the tumor immune microenvironment, have achieved clinical success in melanoma, lymphoma and non-small-cell lung cancer. Although their efficacy as monotherapy in PCa remains limited and optimal patient selection criteria are lacking, emerging evidence suggests that combination immunotherapy regimens may offer clinically significant benefits. This review critically evaluates current clinical trial outcomes involving PD-1/PD-L1 inhibitors for prostate cancer and outlines priority directions for future investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Ch…
- Department of Urology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Zitieren
APA
Hu, G., Li, Z., Chen, Y., Liao, H., & Zhou, S. (2025). Advances in the application of PD-1/PD-L1 immunotherapy for prostate cancer: a review. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1664587
Vancouver
Hu G, Li Z, Chen Y, Liao H, Zhou S. Advances in the application of PD-1/PD-L1 immunotherapy for prostate cancer: a review. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1664587
BibTeX
@article{Hu2025,
author = {Hu, Guangqiang and Li, Zeng and Chen, Yongji and Liao, Hong and Zhou, Shukui},
title = {Advances in the application of PD-1/PD-L1 immunotherapy for prostate cancer: a review},
journal = {Frontiers in Immunology},
year = {2025},
doi = {10.3389/fimmu.2025.1664587}
}
EUVIMED